Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Enliven Therapeutics' CEO, Samuel Kintz, executed sales of common stock on May 1st and 2nd, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Samuel Kintz, the President and CEO of Enliven Therapeutics, sold shares of common stock on May 1st and May 2nd, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
- On May 1st, 5,330 shares were sold at a weighted average price of $20.0763.
- On May 2nd, 2,170 shares were sold at a weighted average price of $20.004.
- Following these transactions, Kintz directly owns 977,892 shares and indirectly owns 980,062 shares through The Kintz & Egan Trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports stock sales under a pre-existing trading plan. It doesn't inherently indicate positive or negative performance.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price, although these sales were pre-planned.
Industry Context
Sales by company executives are a normal part of corporate governance, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to sell shares over a period of time without being accused of trading on non-public information.
Stakeholder Impact
- Shareholders may react to the news of executive stock sales, although the existence of a 10b5-1 plan mitigates potential concerns.
Key Dates
| Date | Description |
|---|---|
| 2019-03-30 | Date of The Kintz & Egan Trust |
| 2024-11-15 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-05-01 | Date of first stock sale |
| 2025-05-02 | Date of second stock sale |
| 2025-05-05 | Date of Form 4 filing |
Keywords
Enliven Therapeutics, ELVN, Samuel Kintz, stock sale, Form 4, Rule 10b5-1, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.